Fixed-dose combination therapy for hypertension

Czech version

Authors: J. Špinar ¹; J. Vítovec ²; L. Špinarová ²
Authors‘ workplace: Interní kardiologická klinika LF MU a FN Brno ¹; I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně ²
Published in: Kardiol Rev Int Med 2016, 18(2): 85-93

Overview

We present an overview of current opinions on the position of fixed-dose combinations in the treatment of hypertension in line with the ESH/ ESC and the Czech Society for Hypertension guidelines of 2013. The most frequently recommended double combinations are a renin angiotensin system inhibitor (ACE-I or sartan) plus a calcium antagonist, a renin angiotensin system inhibitor plus a diuretic, or a calcium antagonist plus a diuretic. A fixed-dose combination of an ACE inhibitor (perindopril), a calcium channel blocker (amlodipine) and a diuretic (indapamide) was introduced in the Czech market in 2014. The main advantage of fixed combinations is improved patient compliance, leading to a better control of hypertension. A triple combination is required for good control of hypertension in about one third of patients.

Keywords:
hypertension – fixed-dose combination – triple combination

Sources

1. Filipovský J, Widimský J jr, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze, verze 2012: Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58: 785– 801.

2. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31: 1281– 1357. doi: 10.1097/ 01.hjh.0000431740.32696.cc.

3. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363– 2369.

4. Cífková R, Škodová Z, Bruthans J et al. Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/ 2008. J Hypertens 2010; 28: 2196– 2203. doi: 10.1097/ HJH.0b013e32833d4451.

5. Bramlage P, Bohm M, Volpe M et al. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patiens. J Clin Hypertens 2010; 12: 666– 677. doi: 10.1111/ j.1751-7176.2010.00322.x.

6. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290– 300. doi: 10.1016/ j.amjmed.2008.09.038.

7. Dahlöf B, Sever PS, Poulter NR et al. The ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895– 906.

8. Kettani FZ, Dragomir A, Côté R et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40: 213– 220. doi: 10.1161/ STROKEAHA. 108.522193.

9. Peters R, Beckett N, Forrete F et al. Incident dementia and blood pressure lowering in the HYpertensiuon in Very Elderly Trial cognitive function assement. Lance Neurol 2008; 7: 683– 689. doi: 10.1016/ S1474-4422(08)70143-1.

10. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121– 2258. doi: 10.1097/ HJH.0b013e328333146d.

11. Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713– 719.

12. Vítovec J, Špinar J. Kombinační léčba hypertenze s přihlédnutím k fixním kombinacím. Kardiol Rev Int Med 2014; 16: 71– 74.

13. Špinar J, Vítovec J. Kombinační léčba hypertenze. Causa Subita 2012; 15: 10– 13.

14. Souček M, Řiháček I. Léčba hypertenze v rámci metabolického syndromu. Kardiol Rev Int Med 2010; 12: 73– 76.

15. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217– 2225.

16. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597– 603.

17. Tobe S, Kawecka-Jaszcz K, Zannad F et al. Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial. J Clin Hypertens (Greenwich) 2007; 9: 120– 127.

18. Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895– 906.

19. Poulter NR, Wedel H, Dahlöf B et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907– 913.

20. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417– 2428. doi: 10.1056/ NEJMoa0806182.

21. Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173– 1181. doi: 10.1016/ S0140-6736(09)62100-0.

22. Vítovec J, Špinar J. Perindopril/ indapamid – fixní kombinace. Remedia 2007; 17: 247– 257.

23. van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin- angiotensin- aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012; 33: 2088– 2097. doi: 10.1093/ eurheartj/ ehs075.

24. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829– 840.

25. Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep 2002; 4: 343– 349.

26. Špinar J, Vítovec J. Kombinační léčba hypertenze. Causa Subita 2012; 15: 10– 13.

27. Hess G, Hill J, Lau H et al. Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. P T 2008; 33: 652– 666.

28. James PA, Oparil S, Carter BL et al. 2014 Evidence-based guideline for the management of high blood pressure in adultsreport from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507– 520. doi: 10.1001/ jama.2013.284427.

29. Deeks ED. Amlodipine/ valsartan/ hydrochlorothiazide: fixed-dose combination in hypertension. Am J Cardiovasc Drugs 2009; 9: 411– 418. doi: 10.2165/ 11204350-000000000-00000.

30. Widimský J jr. První fixní trojkombinace perindopril arginin-indapamid-amlodipin: nový přístup v kombinační léčbě hypertenze. Vnitř Lék 2014; 60: 801– 807.

31. Widimský J jr. Trojkombinace v léčbě hypertenze. Kardiol Rev Int Med 2014; 16: 449– 453.

32. Widimský J jr. Na český trh přichází vůbec první fixní antihypertenzní trojkombinace. Practicus 2014; 8: 29.